Back Back
Lung Cancer Highlights: ASCO 2023

CME

Key Studies in Lung Cancer: Independent Conference Coverage of ASCO 2023

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: August 25, 2023

Expiration: August 24, 2024

Karen Reckamp
Karen Reckamp, MD, MS
Heather Wakelee
Heather Wakelee, MD, FASCO
CME/CE Information

Activity

Progress
1
Course Completed

Introduction

In this module, Heather Wakelee, MD, FASCO, and Karen Reckamp, MD, discuss key findings in the management of lung cancer and other thoracic malignancies presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, including updates in advanced and early-stage non-small-cell lung cancer (NSCLC), extensive-stage small-cell lung cancer (ES-SCLC), and malignant pleural mesothelioma (MPM).

Please note that the slide thumbnails in this activity link to a Capsule Summary PowerPoint slideset for each of the studies discussed. The Capsule Summary slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with lung cancer do you provide care for in a typical month?

In your current practice, how often do you test for EGFR mutations in your patients with newly diagnosed early-stage NSCLC?
Please rate your frequency of testing on a scale of 1 to 7, where 1 is never and 7 is always.

The phase III KEYNOTE-671 trial is evaluating neoadjuvant platinum chemotherapy (CT) plus pembrolizumab or placebo followed by surgical resection and adjuvant therapy with pembrolizumab or placebo, respectively, in patients with early-stage NSCLC. Which of the following most accurately describes the association of tumor PD-L1 expression level with event-free survival (EFS) benefit reported with the addition of perioperative pembrolizumab in this study?

In the phase Ib TROPION-Lung02 trial reported by Goto and colleagues at ASCO 2023, which of the following findings was reported with the addition of platinum CT to different doses of datopotamab deruxtecan in combination with pembrolizumab compared with no added platinum CT?

At ASCO 2023, Leal and colleagues reported results from the phase III LUNAR trial comparing the addition of Tumor Treating Fields (TTFields) with a standard-of-care (SoC) single-agent immune checkpoint inhibitor (ICI; pembrolizumab, nivolumab, or atezolizumab) or docetaxel vs SoC alone as second-line therapy for patients with metastatic NSCLC with disease progression on or after platinum CT. Which of the following patient subgroups demonstrated the largest improvement in median OS outcomes with the addition of TTFields?

BACK | NEXT